Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLAFEM 0.5/35 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years,Oral contraceptive
Prevention of pregnancy (FDA-approved)
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone undergoes hepatic metabolism via reduction and hydroxylation followed by glucuronidation; ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes first-pass metabolism with sulfation and glucuronidation in the gut wall and liver.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: Vd ~4 L/kg (total body water and tissue distribution). Ethinyl estradiol: Vd ~2.5 L/kg.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral bioavailability: norethindrone ~64% (due to first-pass metabolism); ethinyl estradiol ~45% (range 38-55%).
Oral: ~70% due to first-pass metabolism.
No specific dosage adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential adverse effects on renal function and hormonal balance.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). For mild hepatic impairment (Child-Pugh class A), use with caution; no specific dose adjustment but monitor liver function tests.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily per cycle) following standard contraceptive guidelines for adolescents.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women due to lack of contraceptive need and increased risk of cardiovascular events and thromboembolism with estrogen-containing contraceptives.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Ocular changes (retinal thrombosis),Depression,Headache/migraine,Hereditary angioedema exacerbation,Chloasma,Hepatic impairment,Pregnancy discontinuation,Lactation use
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-sensitive neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Age >35 and smoking ≥15 cigarettes/day
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Maintain a balanced diet for overall health.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FIRST TRIMESTER: Increased risk of neural tube defects, cardiovascular malformations, and orofacial clefts with inadvertent exposure; absolute risk estimated at 3-4% above baseline. SECOND TRIMESTER: No direct teratogenic risk, but continue to avoid use due to hormonal effects. THIRD TRIMESTER: Potential for adverse fetal outcomes including respiratory distress, neonatal jaundice, and hypoglycemia; use contraindicated throughout pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated in breastfeeding. Estrogen and progestin are excreted in breast milk; M/P ratio unknown. May reduce milk production and alter milk composition. Theoretical risk of adverse effects in nursing infant. Alternative contraception recommended.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment recommended as use should be discontinued immediately upon confirmed pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
CYCLAFEM 0.5/35 (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) is a monophasic combination oral contraceptive. The 0.5 mg norethindrone dose is lower than typical progestin doses, reducing androgenic side effects. Its lower estrogen content (35 mcg) still provides effective cycle control. It is a first-line option for patients desiring contraception with minimal hormonal exposure. Breakthrough bleeding may occur in the first few cycles, especially with missed pills. Contraindicated in patients with migraine with aura, thrombophilia, or history of estrogen-dependent neoplasia.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill, refer to the package insert instructions; use backup contraception if needed.,Side effects may include nausea, breast tenderness, or spotting, especially during the first few months.,Smoking increases risk of serious cardiovascular events while on this medication; avoid smoking.,This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Notify your healthcare provider before starting new medications, as some (e.g., rifampin, certain anticonvulsants) may reduce effectiveness.,Store at room temperature, away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLAFEM 0.5/35 vs AFIRMELLE, answered by our medical review team.
CYCLAFEM 0.5/35 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLAFEM 0.5/35 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLAFEM 0.5/35 is: One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLAFEM 0.5/35 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLAFEM 0.5/35 is classified as Category C. FIRST TRIMESTER: Increased risk of neural tube defects, cardiovascular malformations, and orofacial clefts with inadvertent exposure; absolute risk estimated at 3-4% above baseline. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.